Drug-related problems and risk factors related to unplanned hospital readmission among cancer patients in Belgium

被引:4
作者
Koubaity, Majda [1 ]
Lechon, Anne-Sophie [1 ]
Amighi, Karim [1 ]
Van Nuffelen, Marc [2 ]
Moreau, Michel [3 ]
Meert, Anne-Pascale [4 ]
De Vriese, Carine [1 ]
机构
[1] Univ Libre Bruxelles ULB, Dept Pharmacotherapy & Pharmaceut, Fac Pharm, Blvd Triomphe,CP 205-07,Access 2,Campus Plaine, B-1050 Brussels, Belgium
[2] Univ Libre Bruxelles, Erasme Hosp, Dept Intens Care & Emergency, Brussels, Belgium
[3] Inst Jules Bordet, Dept Informat Management Unit UGI, Brussels, Belgium
[4] Univ Libre Bruxelles, Inst Jules Bordet, Dept Internal Med, Intens Care Unit & Oncol Emergency, Brussels, Belgium
关键词
Belgium; Drug-related problems; Oncology; Hospital; EVENT REPORTING SYSTEM; PUBLIC VERSION; THROMBOEMBOLISM; POLYPHARMACY; BEVACIZUMAB; COMORBIDITY;
D O I
10.1007/s00520-020-05916-w
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction There are about 60,000 diagnoses of cancer per year in Belgium. After hospital care, about 12-13% of cancer patients are readmitted within 30 days after discharge. These readmissions are partly related to drug-related problems (DRP), such as interactions or adverse drug effects (ADE). Objectives The aim of this study is to quantify and to classify DRP readmissions within 30 days for cancer patients and to highlight risk factors potentially correlated to readmissions. Methods This study is a 6-month observational retrospective study in two care facilities in Brussels: an academic general hospital and an academic oncology center. Patients readmitted within 30 days after their last hospital care for a potential DRP were included. Patient files were evaluated with an intermediate medication review that included interactions analysis (Lexicomp (R)). The probability of DRP readmission was assessed using the World Health Organization's Uppsala Monitoring Centre (WHO-UMC) system. Results The final population included 299 patients; among them, 123 (41.1%) were readmitted due to DRP (certain DRP (4.9%), probable DRP (49.6%), and possible DRP (45.5%)). Risks factors linked to these DRP were a low Charlson Comorbidity Index, polypharmacy, the kind of hospital, and some chemotherapies (platinum preparations). Among all readmitted patients, the D-type interactions were the most common (44.8%), which suggest a possible therapy modification. However, around 10% of interactions were X-type (drug combination to avoid). Conclusion Almost 10% of patient readmitted within 30 days were potentially related to a DRP, most of them from adverse drug effects. Four risk factors (low Charlson Comorbidity Index, polypharmacy, the hospital, and some chemotherapies) were highlighted to prevent these readmissions.
引用
收藏
页码:3911 / 3919
页数:9
相关论文
共 38 条
  • [1] Cancer-associated venous thromboembolism: Burden, mechanisms, and management
    Ay, Cihan
    Pabinger, Ingrid
    Cohen, Alexander T.
    [J]. THROMBOSIS AND HAEMOSTASIS, 2017, 117 (02) : 219 - 230
  • [2] Drug interactions in oncology
    Beijnen, JH
    Schellens, JHM
    [J]. LANCET ONCOLOGY, 2004, 5 (08) : 489 - 496
  • [3] Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer
    Bennett, Charles L.
    Angelotta, Cara
    Yarnold, Paul R.
    Evens, Andrew M.
    Zonder, Jeffrey A.
    Raisch, Dennis W.
    Richardson, Paul
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (21): : 2558 - 2560
  • [4] Hospital Readmissions Necessary Evil or Preventable Target for Quality Improvement
    Brown, Erin G.
    Burgess, Debra
    Li, Chin-Shang
    Canter, Robert J.
    Bold, Richard J.
    [J]. ANNALS OF SURGERY, 2014, 260 (04) : 583 - 591
  • [5] Characteristics of potential drug-related problems among oncology patients
    Bulsink, Arjan
    Imholz, Alex L. T.
    Brouwers, Jacobus R. B. J.
    Jansman, Frank G. A.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2013, 35 (03) : 401 - 407
  • [6] Characteristics of unplanned hospital admissions due to drug-related problems in cancer patients
    Chan, Alexandre
    Soh, Deren
    Ko, Yu
    Huang, Yu-Chu
    Chiang, Joen
    [J]. SUPPORTIVE CARE IN CANCER, 2014, 22 (07) : 1875 - 1881
  • [7] Clinically Significant Drug-Drug Interactions Between Oral Anticancer Agents and Nonanticancer Agents: A Delphi Survey of Oncology Pharmacists
    Chan, Alexandre
    Tan, Seow-Hwei
    Wong, Chen May
    Yap, Kevin Yi-Lwern
    Ko, Yu
    [J]. CLINICAL THERAPEUTICS, 2009, 31 : 2379 - 2386
  • [8] VALIDATION OF A COMBINED COMORBIDITY INDEX
    CHARLSON, M
    SZATROWSKI, TP
    PETERSON, J
    GOLD, J
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 1994, 47 (11) : 1245 - 1251
  • [9] A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION
    CHARLSON, ME
    POMPEI, P
    ALES, KL
    MACKENZIE, CR
    [J]. JOURNAL OF CHRONIC DISEASES, 1987, 40 (05): : 373 - 383
  • [10] How to measure comorbidity: a critical review of available methods
    de Groot, V
    Beckerman, H
    Lankhorst, GJ
    Bouter, LM
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2003, 56 (03) : 221 - 229